GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » The Medicines Co (NAS:MDCO) » Definitions » Beneish M-Score

The Medicines Co (The Medicines Co) Beneish M-Score : 0.00 (As of Apr. 26, 2024)


View and export this data going back to 2000. Start your Free Trial

What is The Medicines Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for The Medicines Co's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of The Medicines Co was 0.00. The lowest was 0.00. And the median was 0.00.


The Medicines Co Beneish M-Score Historical Data

The historical data trend for The Medicines Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Medicines Co Beneish M-Score Chart

The Medicines Co Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.54 -4.14 -3.42 -10.06 -3.34

The Medicines Co Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.09 -3.34 -4.59 -4.61 -1.75

Competitive Comparison of The Medicines Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, The Medicines Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Medicines Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, The Medicines Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where The Medicines Co's Beneish M-Score falls into.



The Medicines Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of The Medicines Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep19) TTM:Last Year (Sep18) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + -0.697 = $-0.70 Mil.
Total Current Assets was $326.73 Mil.
Total Assets was $897.27 Mil.
Property, Plant and Equipment(Net PPE) was $7.42 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.67 Mil.
Selling, General, & Admin. Expense(SGA) was $50.89 Mil.
Total Current Liabilities was $423.14 Mil.
Long-Term Debt & Capital Lease Obligation was $464.99 Mil.
Net Income was -73.994 + -60.055 + -59.865 + -42.474 = $-236.39 Mil.
Non Operating Income was 3.597 + 3.744 + 0.155 + -9.16 = $-1.66 Mil.
Cash Flow from Operations was -60.711 + -48.775 + -49.823 + -39.027 = $-198.34 Mil.
Total Receivables was $0.00 Mil.
Revenue was -3.3 + 1.667 + 7.771 + 8.595 = $14.73 Mil.
Gross Profit was -4.19 + -1.264 + 5.034 + -11.843 = $-12.26 Mil.
Total Current Assets was $187.25 Mil.
Total Assets was $733.74 Mil.
Property, Plant and Equipment(Net PPE) was $10.09 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.28 Mil.
Selling, General, & Admin. Expense(SGA) was $86.43 Mil.
Total Current Liabilities was $77.76 Mil.
Long-Term Debt & Capital Lease Obligation was $669.72 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0) / (0 / 14.733)
= / 0
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-12.263 / 14.733) / (-0.697 / 0)
=-0.832349 /
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (326.729 + 7.421) / 897.27) / (1 - (187.249 + 10.091) / 733.737)
=0.627593 / 0.731048
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0 / 14.733
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.277 / (6.277 + 10.091)) / (2.67 / (2.67 + 7.421))
=0.383492 / 0.264592
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(50.894 / 0) / (86.434 / 14.733)
= / 5.866694
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((464.991 + 423.141) / 897.27) / ((669.724 + 77.757) / 733.737)
=0.989816 / 1.018732
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-236.388 - -1.664 - -198.336) / 897.27
=-0.040554

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.


The Medicines Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of The Medicines Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


The Medicines Co (The Medicines Co) Business Description

Traded in Other Exchanges
N/A
Address
8 Sylvan Way, Parsippany, NJ, USA, 07054
The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The company's primary commercial product, Angiomax, is an anticoagulant drug used in conjunction with aspirin for patients undergoing angioplasty. Medicines recently commercialized a new drug, Cleviprex, which is designed to control blood pressure in intensive-care settings.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Peter Wijngaard officer: Chief Development Officer 8 SYLVAN WAY, PARSIPPANY NJ 07054
Paris Panayiotopoulos director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Geno J Germano director 5 GIRALDA FARMS, MADISON NJ 07940
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christopher T Cox officer: EVP & Chief Corp. Dev. Officer CADWALADER, WICKERSHAM & TAFT LLP, ONE WORLD FINANCIAL CENTER, NEW YORK NY 10281
Fredric N Eshelman director, officer: Executive Chairman PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Armin M Kessler director
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Hiroaki Shigeta director THE MEDICINES COMPANY, 8 SYLVAN WAY, PARSIPPANY NJ 07054
Stuart A Kingsley officer: President and COO 152 CHESTNUT STREET, WEST NEWTON MA 02465
Robert G. Savage director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Glenn Sblendorio director, officer: President & CFO 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
James E Flynn 10 percent owner, other: Possible Members of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Members of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010